Synulox RTU
Active substance
ATC code
Species
Cattle, pigs, dogs and cats.
Indications
This product has bactericidal activity against a broad spectrum of clinically important bacteria found in large and small animals. In vitro the product is active against a wide range of bacteria, including strains resistant to amoxicillin alone because of beta-lactamase production:
Gram-positive
Actinomyces bovis
Bacillus anthracis
Clostridia
Corynebacteria
Peptostreptococcus spp.
Staphylococci
Streptococci
Gram-negative
Actinobacillus lignierisi
Actinobacillus pleuropneumoniae
Bacteroides
Bordetella bronchiseptica
Campylobacter spp.
Escherichia coli
Fusobacterium necrophorum
Haemophilus spp.
Klebsiellae
Moraxella spp.
Pasteurellae
Proteus spp.
Salmonellae
Clinically the product is indicated for the treatment of diseases including:
Cattle
Respiratory infections, soft tissue infections (e.g. joint-ill/navel-ill, abscesses etc.), metritis and mastitis.
Combined Therapy for the treatment of bovine mastitis:
In the situation where systemic treatment as well as intramammary treatment is necessary, Synulox Ready-to-Use injection can be used in combination with Synulox Lactating Cow Intramammary.
Pigs
Respiratory bacterial infections in growing pigs.
Colibacillosis.
Periparturient infections in sows (e.g. mastitis, metritis and agalactia.)
Dogs and Cats
Respiratory tract infections, urinary tract infections and skin and soft tissue infections (e.g. abscesses, pyoderma, anal sacculitis, gingivitis).
Dose to be administered and administration route
By either intramuscular or subcutaneous injection in dogs and cats, and by intramuscular injection only in cattle and pigs, at a dosage rate of 8.75 mg/kg bodyweight (1 ml / 20 kg bodyweight) daily for 3-5 days.
Shake the vial well before use. After injection, massage the injection site. Use a completely dry sterile needle and syringe. Swab the septum before removing each dose.
For combined therapy, the following minimum treatment regime should be followed:
Adverse reactions
Very rarely, the use of the product may result in pain on injection and/or local tissue reactions.
Allergic reactions (allergic skin reactions, anaphylaxis) may occasionally occur.
If allergic reactions occur, the product should be discontinued immediately.
Appropriate symptomatic treatment should be initiated.
The frequency of adverse reactions is defined using the following convention:
- very common (more than 1 in 10 animals treated displaying adverse reaction(s))
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).
References
Similar products
Showing 1 of 1 results
